|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMFA04010428
|
ent-16-epi-13-A4-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2S)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010492
|
ent-16-epi-13-J4-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,5R)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010446
|
ent-17-A4-NeuroP
|
(4Z,7Z)-9-((1S,2S)-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010510
|
ent-17-J4-NeuroP
|
(4Z,7Z)-9-((1R,5R)-5-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010450
|
ent-17-epi-17-A4-NeuroP
|
(4Z,7Z)-9-((1S,2S)-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010514
|
ent-17-epi-17-J4-NeuroP
|
(4Z,7Z)-9-((1R,5R)-5-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010454
|
ent-20-A4-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S)-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopent-3-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010518
|
ent-20-J4-NeuroP
|
(4Z,7Z,10Z)-12-((1R,5R)-5-((R,E)-3-hydroxypent-1-en-1-yl)-4-oxocyclopent-2-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010458
|
ent-20-epi-20-A4-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S)-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopent-3-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010522
|
ent-20-epi-20-J4-NeuroP
|
(4Z,7Z,10Z)-12-((1R,5R)-5-((S,E)-3-hydroxypent-1-en-1-yl)-4-oxocyclopent-2-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010424
|
ent-4,11-diepi-11-A4-NeuroP
|
3-((1R,2S)-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopent-3-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010488
|
ent-4,11-diepi-11-J4-NeuroP
|
3-((1S,5R)-5-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-4-oxocyclopent-2-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010400
|
ent-4,7-diepi-4-A4-NeuroP
|
(S,E)-4-hydroxy-6-((1R,5S)-2-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-3-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010464
|
ent-4,7-diepi-4-J4-NeuroP
|
(S,E)-4-hydroxy-6-((1S,5R)-4-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-2-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010398
|
ent-4-A4-NeuroP
|
(R,E)-4-hydroxy-6-((1S,5S)-2-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-3-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010462
|
ent-4-J4-NeuroP
|
(R,E)-4-hydroxy-6-((1R,5R)-4-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-2-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010420
|
ent-4-epi-11-A4-NeuroP
|
3-((1R,2S)-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopent-3-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010484
|
ent-4-epi-11-J4-NeuroP
|
3-((1S,5R)-5-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-4-oxocyclopent-2-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010402
|
ent-4-epi-4-A4-NeuroP
|
(S,E)-4-hydroxy-6-((1S,5S)-2-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-3-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010466
|
ent-4-epi-4-J4-NeuroP
|
(S,E)-4-hydroxy-6-((1R,5R)-4-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-2-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010408
|
ent-7,10-diepi-7-A4-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,2S)-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010472
|
ent-7,10-diepi-7-J4-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,5R)-5-((2Z,5Z)-octa-2,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010440
|
ent-7,14-diepi-14-A4-NeuroP
|
(Z)-6-((1R,2S)-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010504
|
ent-7,14-diepi-14-J4-NeuroP
|
(Z)-6-((1S,5R)-5-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010406
|
ent-7-A4-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,2S)-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010470
|
ent-7-J4-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,5R)-5-((2Z,5Z)-octa-2,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010436
|
ent-7-epi-14-A4-NeuroP
|
(Z)-6-((1R,2S)-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010500
|
ent-7-epi-14-J4-NeuroP
|
(Z)-6-((1S,5R)-5-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010396
|
ent-7-epi-4-A4-NeuroP
|
(R,E)-4-hydroxy-6-((1R,5S)-2-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-3-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010460
|
ent-7-epi-4-J4-NeuroP
|
(R,E)-4-hydroxy-6-((1S,5R)-4-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-2-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010410
|
ent-7-epi-7-A4-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,2S)-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010474
|
ent-7-epi-7-J4-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,5R)-5-((2Z,5Z)-octa-2,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|